Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03039335 · ClinicalTrials.gov registry record
The Impact of Delayed Diagnosis of Alpha-1 Antitrypsin Deficiency
A clinical trial of Alpha-1 Antitrypsin Deficiency, sponsored by Biocerna.
- Completed
- Registry status
- 43
- Enrollment target
- 1
- Study location
NCT03039335 is a study of Alpha-1 Antitrypsin Deficiency that has completed, run by Biocerna. The registered enrollment target is 43 participants, below the 3,075-participant average among 18 other Alpha-1 Antitrypsin Deficiency trials with a reported enrollment target (99% lower). The trial reports 1 study location across 1 state.
The verdict
NCT03039335, a study of Alpha-1 Antitrypsin Deficiency, has completed, sponsored by Biocerna.
- COMPLETED
- Registry status
- 43 participants
- Enrollment target
- 1
- Study location
Study Summary
The objective of this study is to prospectively assess whether there is any interval between first symptom and initial diagnosis that is experienced by patients with newly diagnosed alpha-1 antitrypsin deficiency (AATD) and then to assess whether this diagnostic interval is associated with worsened clinical status at the time of initial diagnosis.
Conditions Studied
Study Locations (1)
Maryland
- Biocerna LLC - Fulton
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 43 participants |
| Start Date | 2016-12-15 |
| Est. Completion | 2018-04-15 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03039335
The ClinicalTrials.gov registry entry for NCT03039335 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 43 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 3,075-participant average among 18 other Alpha-1 Antitrypsin Deficiency trials with a reported enrollment target (99% lower). The listed sponsor is Biocerna, which has 1 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Alpha-1 Antitrypsin Deficiency appearing as the primary indexed condition, and to 0 interventions.
NCT03039335 reports 1 study location spanning 1 distinct geographic area - top geographies include Maryland.
Frequently Asked Questions
What is clinical trial NCT03039335 about?
NCT03039335 is a clinical study titled "The Impact of Delayed Diagnosis of Alpha-1 Antitrypsin Deficiency". The objective of this study is to prospectively assess whether there is any interval between first symptom and initial diagnosis that is experienced by patients with newly diagnosed alpha-1 antitrypsin deficiency (AATD) and then to assess whether this diagnostic interval is associated with worsened ...
What is the current status of trial NCT03039335?
This trial is currently completed. The enrollment target is 43 participants. The study started on 2016-12-15. Estimated completion is 2018-04-15.
What conditions does trial NCT03039335 study?
This clinical trial studies the following conditions: Alpha-1 Antitrypsin Deficiency.
Who is sponsoring clinical trial NCT03039335?
This trial is sponsored by Biocerna, which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03039335 being conducted?
This trial has 1 study location across Maryland. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Alpha-1 Antitrypsin Deficiency
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Lung Disease and Its Affect on the Work of White Blood Cells in the Lungs
RECRUITING
-
The Alpha-1 Foundation's and University of Florida's Alpha-1 Coded Testing (ACT) Study
RECRUITING
-
PiMZ Longitudinal Cohort (PiMZ Logic)
RECRUITING
-
Long-term, Open-label Study of SAR447537 (INBRX-101) in Adults With Alpha-1 Antitrypsin Deficiency Emphysema
RECRUITING · Phase 2
-
Gene Therapy for Alpha 1- Antitrypsin Deficiency
RECRUITING · Phase 1
-
Alpha-1 Research Registry
RECRUITING
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.